Ophthalmologica最新文献

{"title":"Efficacy of Intravitreal Faricimab for Diabetic Macular Edema and Analysis of Influencing Factors.","authors":"Gong Chen, Zhaohua Zhang, Fanling Meng, Yuechao Zhao, Wen Zheng","doi":"10.1159/oph/aeeag017","DOIUrl":"https://doi.org/10.1159/oph/aeeag017","url":null,"abstract":"<p><strong>Objective: </strong> To evaluate the efficacy and safety of intravitreal faricimab administered under a treat-and-extend (T&E) strategy for DME in a real-world clinical setting, and to analyze factors associated with visual acuity benefits and durability of disease control during interval extension.</p><p><strong>Methods: </strong> This single-center, retrospective cohort study included 170 patients (170 eyes) with diabetic macular edema who initiated intravitreal faricimab treatment between January 2024 and December 2024 and completed at least 12 months of follow-up. Only one eye per patient was included in the analysis. All included eyes completed a three-dose monthly loading phase and were subsequently managed using a faricimab-based treat-and-extend regimen. The primary efficacy endpoints were changes in best-corrected visual acuity (BCVA, ETDRS letters) and central subfield thickness (CST) at 12 months. Key secondary T&E-related endpoints included the total number of injections within 12 months, the maximum treatment interval achieved by month 12, and the proportion of eyes reaching extension intervals of ≥12 and ≥16 weeks. Multivariable linear regression and Cox proportional hazards regression were used to identify exploratory factors associated with visual acuity improvement and time to treatment interval shortening.</p><p><strong>Results: </strong> At 12 months, mean BCVA improved by 9.7 ± 11.5 letters and mean CST decreased by 191.0 ± 135.0 µm (both P < 0.001); 50.0% gained ≥10 letters and 64.7% achieved a dry macula (CST < 300 µm). In multivariable regression, 1-month CST reduction showed the strongest positive association with BCVA gain (B = 0.48 per 100 µm decrease, β = 0.41, P < 0.001), while baseline HbA1c, baseline CST, and ellipsoid zone impairment were negatively associated. Higher baseline HbA1c, CST ≥500 µm, and EZ impairment were associated with interval shortening during the maintenance phase. No serious adverse events occurred.</p><p><strong>Conclusion: </strong> In real-world DME treated with a T&E faricimab regimen, patients achieve sustained functional and anatomical improvements with a favorable safety profile. Twelve-month outcomes and treatment durability were associated with baseline metabolic control, anatomical disease severity, and early CST response, supporting individualized monitoring during treat-and-extend management.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"1"},"PeriodicalIF":2.3,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149207435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The influence of molecular weight on the optical parameters of silicone oil endotamponades for vitreoretinal surgery.","authors":"Niklas Junker, Bryan Calder Ackermann, Sabrina Wohlfart, Gerd Uwe Auffarth, Philipp Uhl, Victor Aristide Augustin, Grzegorz Labuz, Maximilian Hammer","doi":"10.1159/oph/aeeag016","DOIUrl":"https://doi.org/10.1159/oph/aeeag016","url":null,"abstract":"<p><p>Introduction Silicone oil, more specifically polydimethylsiloxane (PDMS) of different molecular weight, is an established endotamponade in vitreoretinal surgery. As emulsification is a feared complication of their intraocular use, high molecular weight compounds (HMWCs) may be added to modify their physicochemical properties lowering emulsification tendency. However, the optical properties of various HMWCs, as well as blends of silicone oils with different fractions of HMWC have never been studied in a controlled laboratory setting and compared with each other. Optical parameters, such as forward light scattering and turbidity, may indicate intermolecular interactions among PDMS fractions with varying molecular weights. Methods Blends of Siluron 1000 and different HMWCs in various ratios were created. Viscosities of the pure HMWC components were 60,000 mPas, 100,000 mPas and 2,500,000 mPas, respectively. Mixtures of Siluron 1000 with 10%, 30% and 90% HWMC component were created. Light scattering of these blends and the raw components was quantified using a custom-made C-Quant straylight meter and turbidity was quantified with an ISO-normed turbidity meter. Light scattering and turbidity were compared between the different mixtures and the raw materials. Additionally, measurement of Dynamic Light Scattering (DLS) using a Zetasizer was performed to quantify the formation of possible particle-like HMWC aggregates. Results Turbidity of PDMS showed a molecular weight-associated increase with the highest turbidity values appearing for pure 2,500,000 mPas HMWC PDMS. For mixtures of Siluron 1000 with 100,000 mPas and 2,500,000 mPas HMWC-PDMS, an increased turbidity was observed when the HMWC component exceeded 10%. Forward light scattering values were very low for all tested samples, slightly increased values were only detectable for mixtures with a proportion of 90% HMWC components. DLS revealed a concentration and molecular weight dependent appearance of particle-like phenomena. Conclusion Although there was no evidence of clinically relevant optical disturbances for all tested substances, the molecular-weight dependent optical properties of HMWC-blends may be attributed to the presence of optically active particles when mixtures exceed a 10% proportion of high-molecular weight components, specifically for 100,000 and 2,500,000 mPas HWMC PDMS. This finding may indicate suboptimal solubility and compromised intermolecular interaction.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"1"},"PeriodicalIF":2.3,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149195978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updated guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).","authors":"Anat Loewenstein, Martin Zinkernagel, Reinier O Schlingemann, Francesco Bandello, Camiel Jf Boon, Ursula Schmidt-Erfurth, Nicole Eter, Caroline C Klaver, Patricia Udaondo, Sandrine A Zweifel, Adnan Tufail, Frank G Holz","doi":"10.1159/oph/aeeag010","DOIUrl":"https://doi.org/10.1159/oph/aeeag010","url":null,"abstract":"<p><p>Since the publication in 2014 of the original EURETINA guidelines for the management of neovascular age-related macular degeneration (nAMD), the treatment landscape for this prevalent and potentially devastating condition has evolved substantially. Along with the introduction of new anti-vascular endothelial growth factor (anti-VEGF) agents and the release of biosimilar agents, anti-VEGF dosing strategies have been refined, and increasing amounts of clinical trial and real-world evidence are available to inform practice. To provide an updated European perspective on nAMD management, the EURETINA panel systematically reviewed European guidelines published since 2014 alongside recent randomized controlled trials and other relevant evidence. Areas of broad consensus across guidelines were identified, including the importance of early diagnosis and prompt initiation of anti-VEGF therapy, and the central role of optical coherence tomography (OCT) in both diagnosis and monitoring. Treat-and-extend regimens are now established as the preferred approach for retreatment, with disease activity defined primarily by changes in retinal fluid accumulation detected by OCT imaging. Recommendations also address follow-up, switching or discontinuing therapy, and referral to low vision support services. Incorporating the EURETINA panel's expertise into this synthesis, this update to the EURETINA guidelines for nAMD provides recommendations to guide high-quality, evidence-based care for patients with nAMD across Europe.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"1"},"PeriodicalIF":2.3,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149170537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subretinal fluid correlates with increased macular volume in diabetic macular edema.","authors":"Hugo Le Boité, Salomé Maunoury, Aude Couturier","doi":"10.1159/oph/aeeag014","DOIUrl":"https://doi.org/10.1159/oph/aeeag014","url":null,"abstract":"<p><strong>Background/objectives: </strong>To determine the prevalence and clinical phenotype of subretinal fluid (SRF) in eyes with diabetic macular edema (DME).</p><p><strong>Methods: </strong>A retrospective study was conducted in treatment-naive patients with DME. The presence of SRF, hard exudates, and cystoid spaces with hyperreflective material (HRM) on OCT B-scans, along with central macular thickness (CMT) in the 1-mm, 3-mm, and 6-mm central areas, were assessed, and the correlation between the presence of SRF and macular thickness was estimated using linear mixed-effects models.</p><p><strong>Results: </strong>Of 101 eyes from 63 patients (49% men, mean age 61.31 ± 9.45 years), 36% had SRF. SRF was significantly and independently associated with macular thickness, with higher 1-mm, 3-mm and 6-mm CMT compared to eyes without SRF (β = 104.7 [95% CI, 53.5; 156] µm, p<0.001; β = 80.5 [95% CI, 45.9; 115.2] µm, p<0.001); β = 55.1 [95% CI, 30.1; 80] µm, p<0.001, respectively). Even though macular thickness was significantly associated with visual acuity, SRF was not associated (β = 0.127 [95% CI, -0.034; 0.287]; p = 0.12). However, in eyes with SRF, width (but not height) of the subretinal fluid was independently associated with lower visual acuity (β = 0.00017; [95% CI: 0.00003 - 0.00031]; p = 0.028).</p><p><strong>Conclusion: </strong>DME patients with SRF exhibited higher macular thickness compared to those without SRF, suggesting SRF is an anatomical marker of a more severe exudative process. However, SRF independent impact on visual acuity was limited and modest in magnitude, suggesting further studies could improve our understanding of the pathophysiological and clinical significance of SRF in DME.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"1"},"PeriodicalIF":2.3,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149137909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicentre Real-World Evaluation of Intravitreal Bevacizumab, Aflibercept, and Ranibizumab for Diabetic Macular Edema.","authors":"Efraim Berco, Orly Yakubovich Fink, Eilon Shcolnik, Michael Ostrovsky, Yuval Kozlov, Raman Tuli, Thomas Kin Man Lee, Ksenia Samocha, Shalhevet Goldfeather Ben Zaken, Nir Shoham-Hazon","doi":"10.1159/oph/aeeag015","DOIUrl":"https://doi.org/10.1159/oph/aeeag015","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the real-world effectiveness and treatment patterns of intravitreal bevacizumab, aflibercept (2 mg), and ranibizumab in patients newly diagnosed with diabetic macular edema (DME).</p><p><strong>Methods: </strong>A retrospective, multicenter observational study with a one-year follow-up was conducted at public clinics in Israel and Canada. A total of 309 eyes from 277 treatment-naive patients with DME were analyzed, including both eyes from 32 patients. Eyes were grouped by first-line therapy: bevacizumab (n=199), aflibercept 2 mg (n=63), or ranibizumab (n=47). The primary endpoint was change in visual acuity (VA) at one year. Secondary endpoints included change in central retinal thickness (CRT), injection frequency, final injection interval, and treatment response metrics. Generalized estimating equation (GEE) models were used to account for inter-eye correlation.</p><p><strong>Results: </strong>At 12 months, VA improved by 6 ETDRS letters with no significant difference between groups in the primary endpoint (p=0.501). In adjusted GEE analyses using bevacizumab as the reference group, aflibercept and ranibizumab were associated with greater CRT reduction (-60.31 µm and -57.24 µm, respectively), longer final injection intervals (+3.52 and +2.58 weeks), and fewer injections over 12 months (-2.05 and -2.21; all p<0.001). Aflibercept was also associated with lower odds of non-response (OR 0.08, p=0.010), and both aflibercept and ranibizumab were associated with lower odds of non-extension (OR 0.08 and OR 0.02, respectively; both p<0.001).</p><p><strong>Conclusions: </strong>In this real-world multicenter cohort, VA improved after anti-VEGF treatment, without a significant between-group difference in the primary visual endpoint. Aflibercept (2 mg) was associated with more favorable secondary anatomical and treatment-burden metrics in adjusted analyses. However, given center-determined treatment allocation and residual baseline CRT imbalance, these findings should be interpreted as exploratory real-world associations rather than definitive evidence of pharmacological superiority. These results highlight the gap between randomized trial efficacy and outcomes observed in routine clinical practice, supporting the need for further practice-based DME research.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"1"},"PeriodicalIF":2.3,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149137915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Faricimab in previously treated nAMD: Real-World Outcomes of a No-Loading-Dose Switching Protocol.","authors":"Scott Lenhof, Thibaud Mathis, Nicolas Lepretre, Jonathan Rencker, Laurent Kodjikian","doi":"10.1159/oph/aeeag012","DOIUrl":"https://doi.org/10.1159/oph/aeeag012","url":null,"abstract":"<p><strong>Introduction: </strong>Evaluate efficacy, anatomical outcomes, and safety of switching to faricimab without a loading dose, using a standardized institutional switch protocol, in patients with previously treated neovascular age-related macular degeneration (nAMD) who achieved a maximum fluid-free interval of 8 weeks or less with aflibercept or ranibizumab.</p><p><strong>Methods: </strong>Retrospective, single-center cohort study conducted at Croix-Rousse Hospital, Lyon and included eyes with a maximum fluid-free interval of 8 weeks or less on aflibercept or ranibizumab, switched to faricimab between November 2023 and December 2024. Eyes were classified as Poor Responders (PR) or Frequent Flyers (FF) based on their prior anti-VEGF response. No loading dose was administered. Primary outcome was change in last intended treatment interval. Secondary outcomes included best-corrected visual acuity (BCVA), SD-OCT parameters, predictors of interval extension and safety.</p><p><strong>Results: </strong>128 eyes were included. Before switching, mean (SD) treatment duration was 36.4 (21.9) months with a mean (SD) 28.2 (17.0) intravitreal injections. After switching, the median gain in the last intended interval was 2.7 [IQR 2.1-3.3] weeks (p<0.001). Subgroup analysis showed a median gain of 3.1 weeks in PR (p<0.001) and 2.4 weeks in FF (p<0.001). BCVA remains stable (p=0.37). Significant reductions were observed in CMT (p<0.001), SHRM (p=0.02), IRF (p<0.001), and SRF (p<0.001). Baseline characteristics were not associated with treatment interval extension. There was one case of anterior uveitis and vitritis, which resolved with topical corticosteroid treatment.</p><p><strong>Conclusion: </strong>In previously treated nAMD patients, switching to faricimab without a loading dose achieved meaningful treatment interval extension, potentially reducing treatment burden without compromising efficacy.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"1"},"PeriodicalIF":2.3,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148930886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carbon Footprint of Outpatient Cataract Surgery in Germany: Multicentre Analysis of Emission Sources, Variability, and Opportunities for Transparent Reporting.","authors":"Franka Wehrle, Hansjürgen Thomas Agostini, Karl Ulrich Bartz-Schmidt, H Burkard Dick, Gerd Geerling, Adrian Gericke, Hans Hoerauf, Christoph Holtmann, Paul Kohlhas, Thabo Lapp, Norbert Pfeiffer, Berthold Seitz, Martin S Spitzer, Maria Steuernagel, Marcus Werner Storch, Suphi Taneri, Focke Ziemssen, Christian Girbardt","doi":"10.1159/oph/aeeag011","DOIUrl":"https://doi.org/10.1159/oph/aeeag011","url":null,"abstract":"<p><p>Introduction Outpatient cataract surgery is one of the most frequently performed surgical procedures worldwide. Reducing its carbon footprint without compromising hygiene and patient safety offers substantial potential for mitigating healthcare-related greenhouse gas emissions. This multicentre study quantified the carbon footprint of outpatient cataract surgery across ten heterogeneous German tertiary centres and examined inter-centre variability in emissions as well as the extent to which current data support transparent, standardised reporting. Methods Between December 2022 and March 2023, standardised on-site assessments collected data on staff and patient travel, electricity consumption, disposable material use, and waste generation. Data were converted into carbon dioxide equivalents (CO₂e) using emission factors from national environmental agencies. Since detailed life cycle and sterilisation data could not be obtained for instrument manufacture and reprocessing, these components were modelled for all centres. Results The centres showed substantial inter-site variation in all major emission categories. Disposable materials (2.53-8.30 kg CO2e) and sterilisation (2.62-7.13 kg CO2e) were the dominant contributors, together accounting for 56.6-84.6% of total emissions. Electricity use contributed 1.0% to 18.5%, whereas waste disposal remained low (≤0.4%). Based on the combination of measured and modelled components, the estimated carbon footprint averaged 14.09 kg CO₂e per cataract procedure (95% CI: 12.08-16.11 kg), with centre-level values ranging from 10.07 to 18.70 kg. Conclusion Substantial emission reductions can be achieved by streamlining material use and improving sterilisation workflow. Transparent reporting that defines system boundaries, specifies uncertainties, and provides access to data collection methods is essential for comparability and for establishing reliable benchmarks in sustainable surgical practice. This study provides a comprehensive multicentre carbon footprint analysis for outpatient cataract surgery in Germany and offers a transparent framework that guides targeted reduction strategies.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"1"},"PeriodicalIF":2.3,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148866226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantification of Straylight Induced by Silicone Oil Adherence and Calcification in Artisan Aphakia and Carlevale Intraocular Lenses.","authors":"Leoni Britz, Niklas Junker, Agnieszka Zielinska, Fabian Jester, Jan Freudenberg, Uwe Bunz, Christian Scholz, Victor Aristide Augustin, Gerd Uwe Auffarth, Maximilian Hammer","doi":"10.1159/oph/aeeag009","DOIUrl":"10.1159/oph/aeeag009","url":null,"abstract":"<p><strong>Introduction: </strong>In lack of capsular support, two commonly used secondary intraocular lens (IOL) fixation strategies include retropupillary iris-claw fixation using the hydrophobic Artisan Aphakia and scleral fixation of the hydrophilic Carlevale IOL. Both models may come into direct contact with endotamponades frequently implanted in the same surgical procedure. The purpose of this laboratory study was to compare the interaction of both IOL models with endotamponades, specifically silicone oil adhesion and calcification, which is more prevalent after exposure to gas endotamponades.</p><p><strong>Methods: </strong>This laboratory study was conducted using Artisan Aphakia (Ophtec, Groningen, Netherlands), Carlevale IOL (Soleko IOL Division, Pontecorvo, Italy), and CT Spheris (Carls Zeiss Meditec, Jena, Germany) as a control. Straylight measurements were carried out with C-Quant straylight meter and used to quantify the effects of both, adherent silicone oil and calcifications in the polymer. Siluron 2000 was used to test silicone oil adhesion. Electrophoresis was used to induce IOL calcification. Calcification was quantified using thermogravimetric analysis and plasma optical emission spectroscopy. Light loss was evaluated using a power meter combined with an optical bench system. The reversibility of silicone oil adhesion was evaluated after usage of F4H5 as a cleansing solution.</p><p><strong>Results: </strong>The Artisan Aphakia was more prone to increased silicone oil adhesion causing a clinically relevant increase in straylight (baseline vs. silicone oil adherence: 3.0 vs. 140.7 deg2/sr; p = 0.002), not fully reversible by using F4H5 as a washout (baseline vs. F4H5 washout: 3.0 vs. 15.3 deg2/sr; p = 0.0019). In contrast, the Carlevale IOL demonstrated a higher susceptibility to calcification (baseline vs. calcification: 2.75 vs. 12.59 deg2/sr).</p><p><strong>Conclusion: </strong>In addition to clinical aspects, such as iris and ciliary body anatomy, the choice of endotamponade in trauma cases can influence the postoperative long-term optical quality of IOLs. Differences between hydrophilic and hydrophobic materials are magnified secondary IOL fixation due to the direct contact to the used endotamponade and should be evaluated during surgical planning.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"1"},"PeriodicalIF":2.3,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148851232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decalin as a Short-Term Endotamponade in Vitrectomy for Persistent Retinal Detachment.","authors":"Karolina Bonińska, Maciej Bednarski, Mitrofanis Pavlidis, Sławomir Cisiecki","doi":"10.1159/oph/aeeag008","DOIUrl":"10.1159/oph/aeeag008","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to evaluate the use of decalin as a short-term endotamponade for the management of severe, persistent retinal detachments.</p><p><strong>Methods: </strong>This retrospective study analyzed 9 eyes of 9 patients in whom decalin was used as an endotamponade. After 2 weeks, it was removed and replaced with silicone oil.</p><p><strong>Results: </strong>Retinal reattachment was achieved in all patients, despite previous surgical failures. The short-term use of decalin proved safe. No complications related to its use, such as retinal toxicity, subretinal migration, inflammatory reactions, or ocular hypertension, were observed.</p><p><strong>Conclusion: </strong>Decalin is a valuable intraoperative tool and effective as a short-term endotamponade.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"1"},"PeriodicalIF":2.3,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148796233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Treatment Interval Extension and Short-Term Interval Stability after Switching to Faricimab in Neovascular AMD: A Mid-Term Observational Study.","authors":"Benjamin Simond, Inès Fenniri, Nicolas Chirpaz, Sandra Elbany, Antonin Rocher, Christelle Gilli, Samuel Chacun, Nicolas Voirin, Carole Burillon, Benjamin Matagrin, Corinne Dot","doi":"10.1159/oph/aeeag007","DOIUrl":"10.1159/oph/aeeag007","url":null,"abstract":"<p><strong>Introduction: </strong>The SHIFT-HB study (SwitcH Faricimab Treatment in High Burden patients) aimed to evaluate the anatomical and functional outcomes - and the short-term stability of extended dosing intervals - after switching to faricimab in high treatment burden (HB) neovascular age-related macular degeneration (nAMD) previously treated with first-generation anti-VEGF agents. The primary aim was to assess treatment interval changes after 6 intravitreal injections (IVIs) and the stability of interval gains between the 5th and 6th faricimab IVI.</p><p><strong>Methods: </strong>Single-center, retrospective real-world study (November 2023-November 2024; tertiary center Edouard Herriot Hospital, Lyon). Eligible eyes had nAMD requiring ≤8-week intervals despite ≥6 prior aflibercept or ranibizumab injections. After the switch, all eyes received ≥6 faricimab IVIs under a proactive Treat-and-Extend regimen. Short-term stability was defined, among eyes with any interval gain, as a prescribed interval at V6 identical to or longer than that at realized at V5.</p><p><strong>Results: </strong>In total, 190 eyes from 158 patients (mean age 81 ± 7.5 years; 57.9% female) were included. The mean pre-switch interval was 4.9 ± 1.2 weeks and increased to 6.7 weeks after 6 faricimab IVIs (p = 5.85 × 10-20). Interval increased in 61.6% of eyes; among these, 45% gained ≥3 weeks (range +3 to +8). Short-term stability between V5 and V6 occurred in 82.3% of responders. The maximum interval was first achieved at V6 in 52.1% of responder eyes. Among eyes with paired baseline and V6 measurements, best-corrected visual acuity remained stable (69.2 vs. 71.2 ETDRS letters; p = 0.67), while central retinal thickness decreased (303.1 µm-287.2 µm; p = 9.98 × 10-4). Intraocular inflammation occurred in 7 eyes (3.7%; 0.61% of injections) and led to drug discontinuation.</p><p><strong>Conclusion: </strong>In real-world HB nAMD, switching to faricimab enabled a significant extension of injection intervals in nearly two-thirds of eyes while maintaining vision and improving OCT anatomy, supporting faricimab as a strategy to reduce treatment burden in this difficult-to-treat population.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"1"},"PeriodicalIF":2.3,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148689507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}